

Take Home Messages - MPNs

New and Impactful Options Across MPNs

Essential Thrombocythemia

- ASA still helpful, perhaps split dose in some
- Hydrea vs PEG INF as Front Line
- Options Coming
 - Bomedemstat
 - ROPEG INFa2b
 - CALR mAB?

Polycythemia Vera

- ASA and PHLEB Still Helpful (HCT <45%)
- ROPEG INFa2b 1L vs Hydrea
- RUX 2L
- New Hepcidin mimetics may play role alone/in combination

Myelofibrosis

- Always be considering BMT
- RUX & FED 1L
- PAC 1L in TPN
- All can be 2L
- MOM likely 2023 1L/2L in Anemia
- Combinations coming
 - Pelabresib
 - Navitoclax
 - Parsiclisib
- Numerous 2L
- CALR mAB

Ruben A. Mesa, MD, FACP

1 President, Enterprise Cancer Service Line Atrium Health
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

